Surmodics Inc (SRDX): Fair Value Consensus

Surmodics, Inc. (SRDX) supplies specialized coatings for pacemaker and stent manufacturers, leveraging patent protection to capture market share in the medtech sector. This price chart reflects a consensus forecast of 42.95, while risks are tied to a limited customer base and potential clinical trial failures. Stable cash flow and long-term royalties provide sustainable demand inertia for the company's innovations.

SRDX (Surmodics Inc) Consensus Target history from 07/04/2022 to 11/29/2025

Analytical breakdowns for Surmodics Corp (SRDX)

- price and consensus price forecast:

Market Chart surmodics.com|SRDX - Price Target Chart

- stock exchange capitalization data:

Market Value Surmodics Corp|SRDX - Enterprise Value

- book capitalization indicators:

Equity per Share Surmodics|SRDX - Company Net Assets|Capitalization to Book Value Ratio surmodics.com|SRDX - Cumulative Company Assets

- debt obligations and liquidity statistics:

- net income and valuation multiples indicators:

SRDX - Company Net Income|Forward Earnings Surmodics, Inc.|SRDX - P/E Multiple|Projected Price to Earnings Ratio Surmodics Inc|SRDX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Surmodics Corp|SRDX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Surmodics|SRDX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months surmodics.com|SRDX - Earnings growth in current year|Expected earnings per share growth for next year Surmodics, Inc.

General company analysis:SRDX - surmodics.com

The strong pricing power of Surmodics, Inc. (SRDX), driven by patents for critical catheter coatings, establishes a foundation for stable business value growth. The trend in the average market price target aggregates institutional analyst expectations, revealing a gap between the current share price and fundamental value, which allows investors to timely identify hidden risks of capital stagnation or the potential for asset undervaluation.

Competitors of Surmodics, Inc.